Etanercept in psoriasis treatment.
More recently, lots of new drugs regulating the several steps of immune reaction have been introduced for psoriasis treatment. These include TNF-alpha inhibitors. One of such inhibitors is Etanercept--a monoclonal antibody connected with human IgG1 binding the soluble form of TNF-alpha receptor. We present the literature data concerning the attempts of Etanercept treatment and local and general complications of its use.
Pietrzak
Aldona
A
Chair and Department of Dermatology, Medical University of Lublin, Lublin, Poland.
Chodorowska
Grazyna
G
Urban
Janusz
J
Roliński
Jacek
J
Pietrzak
Bogusław
B
D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept